Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)

NCT00526617 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT00526617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2007
Completion date
Not reported
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, fallopian tube cancer, hepatocellular carcinoma, metastatic melanoma, non-hematologic malignancies, ovarian cancer, primary peritoneal cancer